MedCompanion

Mucormycosis

Sino-orbital / Disseminated

Source: IDMP View antifungal coverage →
Patient + scenario modifiers
Patient
Clinical scenario / source

Annotations only — chart still shows the full chemistry of each drug.

1. Clinical Syndrome

Angioinvasive infection by Mucorales fungi (Rhizopus, Mucor, Lichtheimia) causing rapidly progressive tissue necrosis. Major forms: rhino-orbital-cerebral (most common in DKA), pulmonary (heme/onc), cutaneous (post-trauma / burn / contaminated dressing), gastrointestinal (rare; very ill / preterm infants), disseminated. Hallmarks: black eschar / necrotic tissue, periorbital swelling with cranial neuropathies, sinus mucosal necrosis, pleuritic chest pain with cavitary lung lesions in heme/onc, rapid progression over hours–days.

2. Pathogens

Consider the patient: Uncontrolled diabetes, especially in DKA (iron-laden / acidotic environment optimal for Mucorales growth); iron overload (deferoxamine therapy in dialysis-dependent patients); hematologic malignancy with prolonged neutropenia; HSCT / SOT; voriconazole prophylaxis breakthrough (Aspergillus prophylaxis selects for Mucorales — classic heme/onc presentation); COVID-associated mucormycosis (CAM, India / SE Asia); penetrating trauma with soil contamination (cutaneous form).

Consider the case: Time-sensitive — every hour of delay increases mortality. Galactomannan and 1,3-β-D-glucan are NEGATIVE in mucormycosis (helps distinguish from Aspergillus). Tissue biopsy is essential — pathology shows broad, ribbon-like, aseptate (or pauciseptate) hyphae at wide (~90°) angles. Send tissue for fungal culture (yield often poor) and PCR if available.

Common

3. Empiric Therapy

TierFirst choiceAlternativesDurationComments
Acute / severe
  • 5–10 mg/kg · q24h · IV · ≥2 weeks induction (then step down per response)

    FIRST-LINE. Higher doses than candidemia / aspergillosis. **URGENT SURGICAL DEBRIDEMENT IS MANDATORY.** Reverse predisposing factors (correct DKA, reduce immunosuppression, stop deferoxamine).

  • 200 mg q8h × 6 → 200 mg daily · q8h then daily · IV/PO

    FDA-approved for mucormycosis. Initial alternative if amphotericin contraindicated; preferred step-down.

  • 300 mg q12h × 2 → 300 mg daily · q12h then daily · IV/PO

    Salvage / step-down. Use delayed-release tablets (300 mg) — superior PK to suspension.

≥2 weeks induction with liposomal amphotericin B (longer if extensive disease); transition to oral azole step-down after clinical/imaging stabilization. Total course typically ≥3–6 months; longer for extensive / cerebral disease.**Time-sensitive — initiate amphotericin and call surgery within hours.** Three pillars: surgery + amphotericin + reverse predisposing factors. Mortality 30–50% even with optimal therapy; rhino-orbital-cerebral with cerebral involvement >70%.
Chronic outpatient
  • 200 mg · PO daily · PO

    STEP-DOWN therapy after stable on amphotericin (typically ≥2 weeks induction). Preferred oral option; fewer drug interactions than posaconazole.

  • 300 mg · PO daily · PO

    Step-down alternative. Use delayed-release tablets — better absorption than suspension. TDM helpful (target trough ≥1 mg/L).

≥3–6 months total; extended if cerebral / extensive disease or persistent immunosuppressionOral step-down after stabilization on liposomal amphotericin (typically ≥2 weeks). Total duration ≥3–6 months minimum; longer for extensive or cerebral disease. Continue until clinical + imaging resolution + recovery from underlying immunosuppression.

4. Directed Therapy

Three pillars — all must be addressed simultaneously:

  1. URGENT SURGICAL DEBRIDEMENT — the single most important intervention. Time-sensitive: every hour of delay kills. Re-look every 24–48 hours; debride to viable tissue. Sino-orbital → ENT urgent; pulmonary → thoracics; cerebral → neurosurgery; cutaneous → plastics / wound care.

  2. Liposomal amphotericin B 5–10 mg/kg/day — start within hours of suspicion, do not wait for confirmation. Higher dose in CNS disease.

  3. Reverse predisposing factors:

    • Correct DKA — restores neutrophil function, alkalinizes pH, decreases free chelatable iron (single biggest non-surgical intervention)
    • Stop deferoxamine if applicable (iron mobilization fuels Mucorales)
    • Reduce immunosuppression as feasible (taper steroids, hold rituximab / CNIs in coordination with transplant / heme team)
    • ANC recovery — G-CSF if neutropenic

Imaging:

  • MRI orbit / brain for rhino-orbital-cerebral (extent of cavernous sinus / cerebral / vascular invasion)
  • CT chest with contrast for pulmonary (vascular invasion, cavitation)
  • Re-image q1–2 weeks to assess progression / response

Step-down to oral azole (isavuconazole preferred, posaconazole tablets alternative) when:

  • Clinical stabilization
  • Imaging response
  • Source controlled by surgery
  • Predisposing factors reversed

Total duration ≥3–6 months; longer for cerebral / extensive disease.

5. Monitoring

Liposomal amphotericin B toxicity:

  • BMP DAILY — nephrotoxicity (Cr ↑), hypokalemia, hypomagnesemia (replete aggressively); transition to PRN once stable
  • Hgb (anemia of inflammation + ampho marrow effect)
  • LFTs weekly
  • Pre-medicate with acetaminophen ± diphenhydramine for rigors; meperidine if severe rigors

Step-down azole toxicity:

  • Isavuconazole: LFTs; QTc (shortens QT — uncommon to be problematic); does not need TDM
  • Posaconazole: LFTs; QTc (prolongs); TDM helpful (trough ≥1 mg/L for treatment); pseudo-aldosteronism (HTN, hypoK)

Disease tracking:

  • Daily clinical exam (lesion progression, new cranial nerve findings)
  • Surgical re-look q24–48 h initially
  • Imaging q1–2 weeks (more often if rapidly progressing)
  • Predisposing factor metrics (glucose / pH for DKA; immunosuppression levels)

Pearls

SURGERY + AMPHOTERICIN + REVERSE PREDISPOSING FACTORS = THREE PILLARS. Missing any pillar → high mortality.

Time-sensitive — start ampho B within hours, call surgery within hours. Mortality 30–50% with optimal therapy; rhino-orbital-cerebral with cerebral involvement >70%.

Galactomannan and 1,3-β-D-glucan are NEGATIVE in mucormycosis — useful to distinguish from Aspergillus. Tissue biopsy is essential — broad, ribbon-like, aseptate hyphae at wide angles.

INTRINSIC RESISTANCE to voriconazole, fluconazole, itraconazole, ALL echinocandins. Only liposomal amphotericin, isavuconazole, and posaconazole have meaningful activity.

Voriconazole prophylaxis breakthrough is a classic heme/onc presentation — Aspergillus prophylaxis selects for Mucorales.

DKA reversal is huge — restores chelatable iron, alkalinizes pH, restores neutrophil function. Sometimes the single most impactful non-surgical intervention.

Step-down to oral isavuconazole (preferred) or posaconazole tablets after ≥2 weeks of stable amphotericin response. Total ≥3–6 months minimum.

COVID-associated mucormycosis (CAM): rapid epidemic surge in India during COVID waves; combination of diabetes, steroids for COVID, and viral immunosuppression. Anticipate increased cases in steroid-treated COVID-19 patients.

References

  • ESCMID-ECMM Joint Clinical Guidelines for the Diagnosis and Management of Mucormycosis (2019)
  • Cornely et al. — Global Guidelines for the Diagnosis and Management of Mucormycosis (Lancet Infect Dis) (2019)
  • ECIL-6 Guidelines on Diagnosis and Treatment of Mucormycosis in Hematologic Malignancy (2017)